AstraZeneca
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
AZ’s first respiratory biologic meets primary endpoints in Phase III trials
September 5, 2016Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma
AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …
AstraZeneca to pay £5.52 million to settle bribery probe
August 31, 2016Research and Development AstraZeneca, SEC, misconduct
According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …
Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront
August 24, 2016Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective
Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …
FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca
August 22, 2016Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III
AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …
Thousands to benefit with new anti-clotting drug recommendation, says NICE
August 12, 2016Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor
The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
Cholesterol drugs drag AstraZeneca’s profits down in latest financial results
July 28, 2016Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results
AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
New drugs to utilise DNA damage response to kill cancer cells
July 26, 2016Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex
The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
AstraZeneca’s Zavicefta meets primary endpoint in Phase III pneumonia trials
July 21, 2016Research and Development Antibiotics, AstraZeneca, zavifecta
AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …
AstraZeneca loses legal bid to block Crestor generics
July 20, 2016Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal
A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …
AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso
July 18, 2016Manufacturing and Production, Research and Development AstraZeneca, Tagrisso
AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …
AstraZeneca mulling a $10-billion bid for Medivation – report
July 12, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …
AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor
July 11, 2016Sales and Marketing AstraZeneca, Crestor, US FDA, patent, regulation
Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from …
AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate
July 6, 2016Research and Development, Sales and Marketing AstraZeneca, Heptares
AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
